These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 9647261)

  • 1. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
    J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-gamma limits macrophage expansion in MRL-Fas(lpr) autoimmune interstitial nephritis: a negative regulatory pathway.
    Schwarting A; Moore K; Wada T; Tesch G; Yoon HJ; Kelley VR
    J Immunol; 1998 Apr; 160(8):4074-81. PubMed ID: 9558118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12 drives IFN-gamma-dependent autoimmune kidney disease in MRL-Fas(lpr) mice.
    Schwarting A; Tesch G; Kinoshita K; Maron R; Weiner HL; Kelley VR
    J Immunol; 1999 Dec; 163(12):6884-91. PubMed ID: 10586090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease.
    Moore KJ; Yeh K; Naito T; Kelley VR
    J Immunol; 1996 Jul; 157(1):427-32. PubMed ID: 8683148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
    Lenda DM; Stanley ER; Kelley VR
    J Immunol; 2004 Oct; 173(7):4744-54. PubMed ID: 15383612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E; Lenda DM; Kelley VR
    J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis.
    Faust J; Menke J; Kriegsmann J; Kelley VR; Mayet WJ; Galle PR; Schwarting A
    Arthritis Rheum; 2002 Nov; 46(11):3083-95. PubMed ID: 12428253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
    Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
    Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced response of macrophages to CSF-1 in autoimmune mice: a gene transfer strategy.
    Moore KJ; Naito T; Martin C; Kelley VR
    J Immunol; 1996 Jul; 157(1):433-40. PubMed ID: 8683149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM; Turner JE; Paust HJ; Lindner M; Peters A; Heiss K; Velden J; Hopfer H; Fehr S; Krieger T; Meyer-Schwesinger C; Meyer TN; Helmchen U; Mittrücker HW; Stahl RA; Panzer U
    J Immunol; 2009 Oct; 183(7):4693-704. PubMed ID: 19734217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice.
    Haas C; Ryffel B; Le Hir M
    J Immunol; 1997 Jun; 158(11):5484-91. PubMed ID: 9164971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice.
    Tada Y; Nagasawa K; Ho A; Morito F; Koarada S; Ushiyama O; Suzuki N; Ohta A; Mak TW
    J Immunol; 1999 Sep; 163(6):3153-9. PubMed ID: 10477582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephritogenic cytokines and disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets.
    Wada T; Schwarting A; Chesnutt MS; Wofsy D; Rubin Kelley V
    Kidney Int; 2001 Feb; 59(2):565-78. PubMed ID: 11168938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
    Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
    Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic expression of Fas in T cells blocks lymphoproliferation but not autoimmune disease in MRL-lpr mice.
    Fukuyama H; Adachi M; Suematsu S; Miwa K; Suda T; Yoshida N; Nagata S
    J Immunol; 1998 Apr; 160(8):3805-11. PubMed ID: 9558084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inducible co-stimulator null MRL-Faslpr mice: uncoupling of autoantibodies and T cell responses in lupus.
    Zeller GC; Hirahashi J; Schwarting A; Sharpe AH; Kelley VR
    J Am Soc Nephrol; 2006 Jan; 17(1):122-30. PubMed ID: 16291836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRL/lpr and MRL+/+ macrophage DNA synthesis in the absence and the presence of colony-stimulating factor-1 and granulocyte-macrophage colony-stimulating factor.
    Hamilton JA; Chan J; Byrne RJ; Bischof RJ; Jaworowski A; Kanagasundaram V
    J Immunol; 1998 Dec; 161(12):6802-11. PubMed ID: 9862711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha.
    Rifkin IR; Channavajhala PL; Kiefer HL; Carmack AJ; Landesman-Bollag E; Beaudette BC; Jersky B; Salant DJ; Ju ST; Marshak-Rothstein A; Seldin DC
    J Immunol; 1998 Nov; 161(10):5164-70. PubMed ID: 9820486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FcgammaRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease.
    Yajima K; Nakamura A; Sugahara A; Takai T
    Eur J Immunol; 2003 Apr; 33(4):1020-9. PubMed ID: 12672068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.